KOL

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

United States Radiology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Radiology, Professional Services, Health, Human Resources, Physician, Perception, FMV, KOL, Insurance

The "Fair-Market Value Compensation Rates for Radiology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Radiology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • Thought Leader Compensation US Radiology report presents fair-market value (FMV) hourly and half-day compensation rates for US-based KOLs in the Radiology specialty, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

United States Rheumatology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Hospitals, Thought Leadership, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Professional Services, Physician, Research, Internet, Perception, FMV, KOL, Insurance

The "Fair-Market Value Compensation Rates for Rheumatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Rheumatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • Thought Leader Compensation US Rheumatology report presents fair-market value (FMV) hourly and half-day compensation rates for U.S. KOLs - Rheumatology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

United States Gastroenterology KOLs Fair-Market Value Compensation Rates Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Hospitals, Practice Management, Human Resources, General Health, Physician, Research, Internet, Perception, FMV, KOL, Insurance

The "Fair-Market Value Compensation Rates for Gastroenterology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Gastroenterology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • Thought Leader Compensation US Gastroenterology report presents fair-market value (FMV) hourly and half-day compensation rates for US-based KOLs in Gastroenterology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

United States Dermatology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Thought Leadership, Practice Management, Other Health, General Health, Biotechnology, Physician, Dermatology, Perception, Research, KOL, Health professional, Insurance

The "Fair-Market Value Compensation Rates for Dermatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Dermatology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • KOL FMV Rates Dermatology USA presents fair-market value compensation rates for US-based Dermatology KOLs, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national, and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

United States Neurology KOLs Fair-Market Value Compensation Rate Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Neurology, Thought Leadership, Physician, Perception, Research, KOL, Health professional, Insurance

The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fair-Market Value Compensation Rates for Neurology KOLs - United States" report has been added to ResearchAndMarkets.com's offering.
  • Thought Leader Compensation US Neurology presents fair-market value compensation rates for US-based KOLs in neurology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national, and local).
  • These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs).
  • Establishing fair-market value compensation rates will:
    Reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.

How Labor Shortages and Telehealth Impact HCP Targeting: Best Practices Using Claims Insights, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Physician, HCP, Patient, Marketing, Innovation, KOL, Nursing

TORONTO, March 20, 2024 /PRNewswire-PRWeb/ -- From a surge in telehealth utilization to worsening healthcare provider (HCP) shortages and workloads to shrinking provider access and density, traditional visits by sales representatives are fading. In this webinar, the attendees will get to learn about the importance of updating HCP targeting strategies and adapting to the changing healthcare landscape, especially trends impacting HCPs and how they interact with life sciences sales representatives. They will also get to learn how medical claims-based intelligence can deliver actionable insights to help life sciences teams modernize their marketing and sales efforts.

Key Points: 
  • TORONTO, March 20, 2024 /PRNewswire-PRWeb/ -- From a surge in telehealth utilization to worsening healthcare provider (HCP) shortages and workloads to shrinking provider access and density, traditional visits by sales representatives are fading.
  • In this webinar, the featured speaker will present best practices for navigating market dynamics and creating sales territory alignment planning based on the physician landscape.
  • In this webinar, the featured speaker will present best practices for navigating market dynamics and creating sales territory alignment planning based on the physician landscape.
  • Register for this webinar to learn the importance of updating HCP targeting strategies and adapting to the changing healthcare landscape.

Kuaishou Technology Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Online, Astral, Real estate, Algorithm, Ecosystem, UAL, MAU, Sale, Shithead (card game), Investment, Maus, Depreciation, Cosmetics, Marketing, Employment, Education, City, Nio, Social Security, Sport, Average cost, Agriculture, KOL, Acquisition, Role, Video, Telephone numbers in Hungary, GMV, Double, Health, Culture, Growth, Operating cost, DAU, Social, Music, Total, Video game

Users continue to choose Kuaishou, and our MAUs exceeded 700 million in the fourth quarter, marking a new record high.

Key Points: 
  • Users continue to choose Kuaishou, and our MAUs exceeded 700 million in the fourth quarter, marking a new record high.
  • Revenue from our live streaming business remained stable at RMB10.0 billion for the fourth quarter of 2023 and 2022, respectively.
  • In the fourth quarter of 2023, average MAUs on the Kuaishou App exceeded 700 million, marking another new record.
  • Based on our refined operation strategy, the subsidy cost per DAU of Kuaishou Express declined year-over-year in the fourth quarter of 2023.

Grwth Army Launches in Partnership with GDA Capital to Revolutionize Web3 Growth Marketing and Investment

Retrieved on: 
Tuesday, March 5, 2024
Marketing, Growth, KOL, Entrepreneurship, Partnership, Cryptocurrency

"Our joint venture with GDA Capital embodies our mutual commitment to harnessing the full spectrum of marketing capabilities to revolutionize the web 3.0 space.

Key Points: 
  • "Our joint venture with GDA Capital embodies our mutual commitment to harnessing the full spectrum of marketing capabilities to revolutionize the web 3.0 space.
  • The partnership with GDA Capital brings a wealth of experience and expertise to Grwth Army.
  • GDA Capital's proven track record in digital asset investment and capital markets advisory services complements Grwth Army's focus on KOL-driven marketing distribution and growth strategies.
  • "GDA Capital has always been at the forefront of innovation in the digital asset space," said Michael Gord, Founder at GDA Capital.